Potential Impact of Postoperative Early Complications on the Timing of Adjuvant Chemotherapy in Patients Undergoing Radical Cystectomy: A High-Volume Tertiary Cancer Center Experience

European Urology

Volumn 55, Issue 1, 2009, Pages 177-186

  Donat, S Machele ^a   Shabsigh, Ahmad ^a   Savage, Caroline ^a   Cronin, Angel M ^a   Bochner, Bernard H ^a   Dalbagni, Guido ^a   Herr, Harry W ^a   Milowsky, Matthew I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant chemotherapy; Bladder cancer; Postoperative complications; Radical cystectomy

Indexed keywords

CISPLATIN;

ADJUVANT THERAPY; ARTICLE; BLADDER CANCER; BLADDER SURGERY; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER SURGERY; CARDIOVASCULAR DISEASE; CYSTECTOMY; GASTROINTESTINAL SYMPTOM; HOSPITAL READMISSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; NEUROLOGICAL COMPLICATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REOPERATION; THROMBOEMBOLISM; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; WOUND INFECTION;

AGED; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 56249148146     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.07.018     Document Type: Article

References (25)

1. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349 (2003) 859-866
2. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361 (2003) 1927-1934
3. Winquist I., Kirchner T.S., Segal R., Chin J., and Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 171 (2004) 561-569
4. Herr H.W., Dotan Z., Donat S.M., and Bajorin D.F. Defining optimal therapy for muscle invasive bladder cancer. J Urol 177 (2007) 437-443
5. Kassouf W., Spiess P.E., Brown G.A., et al. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol 52 (2007) 769-776
6. Schrag D., Mitra N., Xu F., et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology 65 (2005) 1118-1125
7. David K.A., Milowsky M.I., Ritchey J., Carroll P.R., and Nanus D.M. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the national cancer data base. J Urol 178 (2007) 451-454
8. Lehmann J., Retz M., and Stockle M. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy. World J Urol 20 (2002) 144-150
9. Sonpavde G., and Petylak D.P. Perioperative chemotherapy for bladder cancer. Crit Rev Oncol/Hematol 57 (2006) 133-150
10. Raghavan K., Quinn D., Skinner D.G., and Stein J.P. Surgery and adjunctive chemotherapy for invasive bladder cancer. Surg Oncol 11 (2002) 55-63
11. Millikan R., Dinney C., Swanson D., et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 19 (2001) 4005-4013
12. Konety B.R., Allareddy V., and Herr H. Complications after radical cystectomy: analysis of population-based data. Urology 68 (2006) 58-64
13. Jaques D.P. Measuring morbidity. Ann Surg 240 (2004) 214-215
14. Martin II R.C.G., Brennan M.F., and Jaques D.P. Quality of complication reporting in the surgical literature. Ann Surg 235 (2002) 803-813
15. Donat S.M. Standards for surgical complication reporting in urologic oncology: time for a change. Urology 69 (2007) 221-225
16. Miller D.C., Filson C.P., Wallner L.P., Montie J.E., Campbell D.A., and Wei J.T. Comparing performance of morbidity and mortality conference and national surgical quality improvement program for detection of complications after urologic surgery. Urology 68 (2006) 931-937
17. Hollenbeck B.K., Miller D.C., Taub D., et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol 174 (2005) 1231-1237
18. Hollenbeck B.K., Miller D.C., Taub D.A., et al. The effects of adjusting for case mix on mortality and length of stay following radical cystectomy. J Urol 176 (2006) 1363-1368
19. Trotti A., Colevas A.D., Setser A., et al. CTCAE v. 3.0: development of a comprehensive grading system for adverse events of cancer treatment. Semin Radiat Oncol 13 (2003) 176-181
20. Loehrer Sr. P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10 (1992) 1066-1073
21. Logothetis C.J., Dexeus F., Sella A., et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors. J Clin Oncol 8 (1990) 1050-1055
22. Saxman S., Propert K., Einhorn L.H., et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial cancer: a cooperative group study. J Clin Oncol 15 (1997) 2564-2569
23. Von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000) 3068-3077
24. Dash A., Galsky M.D., Vickers A.J., et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107 (2006) 506-513
25. Raj G.V., Iasonos A., Herr H., and Donat S.M. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin based chemotherapy in bladder cancer. J Clin Oncol 24 (2006) 3095-3100